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Patients with Alport’s syndrome develop a number of pro-
inflammatory cytokine and matrix metalloproteinase (MMP)
abnormalities that contribute to progressive renal failure.
Changes in the composition and structure of the glomerular
basement membranes likely alter the biomechanics of cell
adhesion and signaling in these patients. To test if enhanced
strain on the capillary tuft due to these structural changes
contributes to altered gene regulation, we subjected cultured
podocytes to cyclic biomechanical strain. There was robust
induction of interleukin (IL)-6, along with MMP-3, -9, -10,
and -14, but not MMP-2 or -12 by increased strain.
Neutralizing antibodies against IL-6 attenuated the strain-
mediated induction of MMP-3 and -10. Alport mice treated
with a general inhibitor of nitric oxide synthase (L-NAME)
developed significant hypertension and increased IL-6 and
MMP-3 and -10 in their glomeruli relative to those of
normotensive Alport mice. These hypertensive Alport mice
also had elevated proteinuria along with more advanced
histological and ultrastructural glomerular basement
membrane damage. We suggest that MMP and cytokine
dysregulation may constitute a maladaptive response to
biomechanical strain in the podocytes of Alport patients,
thus contributing to glomerular disease initiation and
progression.
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The glomerular basement membrane (GBM) in Alport
syndrome is irregularly thickened and thinned, with a
multilaminar or ‘basketweave’ appearance that is unique to
the disease and a definitive diagnostic test for Alport
syndrome. Immunostaining shows extracellular matrix de-
posits in the thickened regions.1 More recently, it was shown
that the thickened regions are more permeable to injected
ferritin than the non-thickened regions of the GBM.2 This
property is consistent with a partially degraded matrix
network, suggesting that proteolytic damage may contribute
to focal thickening of the Alport GBM. The type IV collagen
network in the Alport GBM is comprised entirely of a1(IV)
and a2(IV) chains. This network contains fewer interchain
crosslinks than wild-type GBM,3 and is more susceptible to
proteolytic degradation by endogenously expressed matrix
metalloproteinases (MMPs).4 Glomerular MMPs have been
shown to be induced in the glomeruli of Alport mice, and
blocking the activity of specific MMPs has been shown to
ameliorate the progression of glomerular pathology.4–6
The delayed onset in Alport syndrome suggests that the
glomerulus is subjected to chronic insult that eventually
results in activation of the disease process. There are at least
two potential sources of insult. One is the persistence of the
embryonic-like basement membrane and its failure to
program podocyte cell signaling appropriately. This could
result from a GBM lacking the a3/a4/a5 collagen network for
binding and activating the aVb3 collagen receptor, for
example Borza et al.7 A second explanation is the distinct
physical properties (thinner, less cross-linked) of the Alport
GBM, which is likely more elastic, subjecting the podocytes
to elevated biomechanical strain even under normal glomer-
ular blood pressure. As the disease progresses and nephron
mass is lost, glomerular hypertension develops, further
exacerbating the biomechanical strain and the effector
functions influenced by it.
Cell culture systems for studying the influence of
biomechanical strain have relied on specialized instruments
in which cells are plated on elastic membranes, which can be
stretched precisely using computer-assisted programs. These
systems have been used extensively in studies of skin,
cardiomyocytes, and bone cells, in which biomechanical
strain would be expected to have important biological
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consequences. The varied studies have provided a wealth
of information regarding how cell adhesion, cytoskeletal
dynamics, and cell signaling machinery respond to strained
adhesive interactions between cells and extracellular matrix.8
More recently, glomerular podocytes have been studied as a
means of understanding how glomerular hypertension
contributes to progressive glomerular diseases. These studies
noted the influences of mechanical strain on maladaptive
responses such as activation of the tissue angiotensin system9
and induction of SPARC (Secreted Protein Acidic and Rich in
Cysteine),10 changes that promote glomerulosclerosis. Con-
versely, adaptive responses of podocytes to mechanical strain
were also documented, in which induction of osteopontin
enhances cytoskeletal reorganization and protects against
strain-induced podocyte loss.11 The relevance of these
findings was often confirmed in vivo using hypertensive
mouse or rat models.9,10
In this study, we used in vitro and in vivo approaches to
examine a potential role for biomechanical strain in
regulating the expression of MMPs known to contribute to
GBM destruction in Alport mouse models. The results
suggest that biomechanical strain leads to maladaptive gene
regulation in Alport mice, which may constitute an
important mechanism for GBM disease initiation and
progression.
RESULTS
a3b1 integrin binding to the a5 chain of laminin 521 is a
principal adhesive interaction between podocytes and the
GBM. Earlier studies of biomechanical strain responses in
podocytes were conducted on plates pre-coated with collagen
I, which is not a component of GBM.9–11 To determine
whether matrix influences the expression of MMP-3, -10, and
interleukin-6 (IL-6) in cultured podocytes, differentiated
wild-type podocytes were cultured on plastic plates pre-
coated with either collagen I, placental laminin, or a coating
of collagen I followed by a second coating with placental
laminin (Flexcell plates are pre-coated with collagen-1). After
48 h, cells were harvested and basal levels of expression of
MMP-3, -10, and IL-6 were examined by real-time reverse
transcriptase (RT)-PCR. The results in Figure 1 show that
cells cultured on placental laminin had lower basal levels of
mRNA expression for MMP-3, -10, and IL-6 compared with
the cells cultured on collagen I.
We employed the Flexcell system (Flexcell International,
Hillsborough, North Carolina, USA) to subject podocytes
to a 10% cyclical stretch for 15 h on elastic wells coated
with collagen I/placental laminin. RNA was analyzed by
conventional RT-PCR for MMP-2, -3, -9, -10, -12, and -14.
The results in Figure 2 show MMP-2 and -12 mRNA
expression are not influenced by mechanical stretch. In
contrast, MMP-3, -9, -10, and 14 are robustly induced by
stretch. Cyclophilin and GAPDH were used as controls, and
showed no response and consistent loading.
Interleukin-6 has been implicated in the regulation of
stromelysins in other systems,12,13 and it is induced early in
Alport glomeruli (unpublished observation). On the basis of
this, we focused our efforts on characterizing the stretch-
mediated response of the stromelysins (MMP-3 and -10) and
IL-6. We performed mechanical stretch response experiments
and analyzed RNA by real-time RT-PCR using Taqman
probes for stromelysins 1 and 2 (MMP-3 and -10), as well as
for IL-6 normalized to GAPDH. Figure 3a shows robust
stretch-mediated induction of MMP-3, -10, and IL-6 in
podocytes.
IL-6 might contribute to the induction of MMP-3 and -10
mRNAs through an autocrine loop mechanism. To test this,
we added IL-6-neutralizing antibodies to the media before
applying mechanical strain and found partially blocked
induction of both MMP-3 and -10 mRNAs (Figure 3b). To
further test this, we treated differentiated podocytes cultured
on collagen/placental laminin with recombinant IL-6. As
shown in Figure 3c, mRNAs encoding both MMP-3 and -10,
but not IL-6, are induced by recombinant IL-6.
The loss of adhesion resulting from biomechanical stresses
is known to affect changes in the actin cytoskeleton. It is well
established that a-actinin-4 interacts with synaptopodin.14
Synaptopodin functions in regulating the actin-bundling
activity of a-actinin-4, a key regulator of actin organization
in the podocyte.15,16 We examined the cytoskeletal organiza-
tion in wild-type podocytes cultured on laminin by dual
immunostaining with antibodies specific for either a-actinin-
4 or synaptopodin, or with phalloidin to stain the actin
cytoskeleton directly. Figure 4a–d shows that wild-type cells
have fine filamentous staining for actin (Figure 4d) with
discrete regions of co-localization for a-actinin-4 and
synaptopodin at the peripheral processes of the cells (Figure
4a–c). After 15 h of 10% cyclic biomechanical stretch,
disruption of filamentous synaptopodin and a-actinin-4
co-localization (Figure 4e–g), and disorganized actin
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Figure 1 |Basal level of expression for matrix
metalloproteinase (MMP)-3 and -10, and IL-6 are lower for
cells cultured on placental laminin than on collagen I.
Glomerular podocytes were differentiated for 2 weeks and plated
on plastic coated with placental laminin, collagen I, and then
laminin, or collagen I alone. After 48 h, RNA was isolated and
analyzed for the indicated transcripts by real-time PCR. Data
points represent results from two independent experiments run in
triplicate, with standard deviations. On the basis of these findings,
we carried out all mechanical stretch experiments on plates
coated with placental laminin, as this is the predominant ligand
for a3b1 integrin in the glomerular basement membrane.45,46
Col I, collagen I; Lam, laminin; Wt, wild type.
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filaments (Figure 4h) were observed, suggesting strain-
mediated disruption of the actin cytoskeleton.
To examine the effects of mechanical strain in vivo, we
induced a state of hypertension by administering N-nitro-L-
arginine methyl ester salts (L-NAME), a method widely
employed in both rat and mouse models.17,18 We used the
CODA-2 (Kent Scientific, Torrington, CT, USA) non-invasive
tail-cuff system for measuring blood pressure. The C57 Bl/6
X-linked Alport mouse model was employed because the
slower disease progression in this background19,20 allowed
blood pressure measurements to be made in fully grown
mice, providing better consistency across longitudinal
measures. Baseline measures of systolic blood pressure were
around 135±12 mm of Hg, consistent with published results
using intra-arterial methodologies.21 L-NAME-treated mice
showed consistently increased systolic blood pressure to
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Figure 2 |Mechanical strain induces matrix metalloproteinase
(MMP)-3, -9, -10, and -14 mRNA expression in cultured
podocytes. Glomerular podocytes were cultured on elastic
membranes coated first with collagen I and then with placental
laminin and subjected to 10% cyclic stretch using the FlexCell
system. After 15 h, mRNA was isolated and analyzed by reverse
transcriptase (RT)-PCR for mRNAs encoding the indicated MMPs.
Cyclophilin and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNAs were included as loading controls. Results shown
are characteristic of several similar experiments.
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Figure 3 |Biomechanical strain induces IL-6, matrix
metalloproteinase (MMP)-3, and -10 in cultured podocytes,
and IL-6 contributes to elevated MMP-3 and -10 expression
through an autocrine loop. (a) Differentiated podocytes were
plated onto elastic membranes pre-coated with collagen I, and
then with placental laminin. Cultures were subjected to 10% cyclic
mechanical strain for 15 h, and the RNA was isolated and analyzed
by real-time PCR for the indicated transcripts. (b) IL-6-neutralizing
antibodies partially ameliorate the strain-mediated induction of
MMP-3 and -10. Glomerular podocytes were cultured on plates
coated with collagen I and placental laminin in medium
containing either neutralizing antibodies against IL-6 or an
isotype-matched control antibody. Cells were subjected to 10%
biomechanical strain for 15 h, and total RNA was analyzed by real-
time quantitative reverse transcriptase (qRT)-PCR using TaqMan
probes specific for either MMP-3 or -10. (c) Recombinant IL-6
induces MMP-3 and -10 mRNA expression levels in podocytes
cultured on placental laminin. Differentiated podocytes were
plated on plates pre-coated with placental laminin. Cells were
harvested after 24 h and analyzed for expression of mRNAs
encoding MMP-3 and -10, and IL-6. A significant increase in MMP-
3 and -10 expression was observed at all three concentrations of
recombinant IL-6 tested relative to untreated control cells. For all
three experiments, amplifications were done in multiplex with
TaqMan probes specific for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), which was used to normalize the data.
Bars represent mean and standard deviations. GAPDH was run
with all samples to control for loading. Data represent statistically
analyzed results for at least five independent experiments run in
triplicate. Asterisks denote significance (Po0.05). N. Ab,
neutralizing antibodies; Str, strain.
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170±16 mm of Hg in both wild-type and Alport mice.
Figure 5 shows the results of a longitudinal study. The salt-
treated animals also showed higher systolic blood pressures
and urinary albumin levels (Figure 5I). In Figure 5II we
express the data showing albuminuria as a function of
systolic blood pressure. The correlation of higher blood
pressure corresponding to higher albuminuria is independent
of the age of the mice. When all of the data for all ages are
plotted together, a highly significant correlation coefficient
shows a statistically significant relationship between systolic
blood pressure and albuminuria. It is notable that L-NAME-
treated mice with lower blood pressure also showed lower
albuminuria.
Elevated albuminuria likely indicates more advanced
glomerular pathology in salt-treated hypertensive Alport
mice. To test this, we performed immunofluorescence
immunostaining of 10-week-old wild-type and salt-treated
Alport mice (treated from 6 to 10 weeks of age) using
antibodies specific for fibronectin or the a2 chain of laminin.
Fibronectin staining, which is restricted to the mesangial
matrix, shows significantly expanded mesangium in salt-
treated Alport mice relative to Alport mice given no salt
(Figure 6a–c). Laminin a2, which is normally restricted to the
mesangial matrix in the glomerulus, is known to accumulate
in the the GBM of Alport mice.22,23 In salt-treated Alport
mice, we observed massive accumulation of laminin a2 in
nearly every portion of every capillary loop (Figure 6f),
whereas in no-salt Alport animals, there was punctate GBM
immunostaining for laminin a2 (Figure 6e), consistent with
less advanced glomerular disease compared with salt-treated
mice. These findings were confirmed by transmission
electron microscopy (Figure 6). Salt-treated Alport mice
invariably showed extensive GBM damage with irregular
thickening and multilamination, whereas no-salt animals
showed much less damage. None of these effects were
observed in salt-treated wild-type mice (data not shown).
Next, we examined the in vivo relevance of biomechanical
strain-mediated induction of MMP-3, -10, and IL-6 in
cultured podocytes. We used the 129 Sv strain for this
experiment because of the rapid disease progression com-
pared with the C57 Bl/6 background,20 resulting in consistent
molecular changes related to glomerular disease. The kinetics
of MMP-3, -10, and IL-6 mRNA induction in Alport mice on
the 129 Sv background (data not shown) predicted that the
window between 4 and 5 weeks of age would be the most
informative. We treated wild-type mice or Alport mice with
salt or no salt from 4 to 5 weeks of age. Figure 7I shows that,
like the C57Bl/6 X-linked Alport mice, the salt-treated 129 Sv
autosomal Alport mice show elevated systolic blood pressure
and elevated levels of proteinuria relative to animals given no
salt. Wild-type mice occasionally showed microalbuminuria
in response to salt treatment as well, suggesting that some of
the elevated proteinuria might be due to direct effects of
hypertension on glomerular filtration. Glomeruli were
isolated from these mice and RNA analyzed by real-time
PCR for MMP-3, -10, -12, and IL-6 mRNAs. MMP-12 was
analyzed because it is known to be induced as a function of
Alport glomerular disease progression,5 but was not found to
Wild type
α-actinin-4 Synaptopodin Dual Phalloidin
Wild-type
stretch
Figure 4 |Biomechanical strain leads to disruption of the cytoskeleton in wild-type podocytes. (a–d) Differentiated wild-type
podocytes were plated onto Flexcell plates with placental laminin. Cells were immunostained with antibodies specific for a-actinin-4 (a),
synaptopodin (b), or phalloidin (d). Dual-channel immunostaining shows co-localization of the synaptopodin and a-actinin-4 (c). (e–h)
Immunostaining of podocytes on laminin after 15 h of 10% cyclic biomechanical stretching on the Flexcell system. Intracellular filaments are
disrupted, and anchoring filaments no longer stain positive for synaptopodin, suggesting that mechanical strain results in disruption of
both the actin cytoskeleton (phalloidin staining in H) and destabilization of the synaptopodin/a-actinin-4 protein interactions (e–g), which
are known actin-bundling proteins involved in actin cytoskeletal dynamics.14
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be induced by biomechanical strain in our cell culture studies
(Figure 2). The results in Figure 7II show that salt-treated
Alport mice have significantly elevated levels of MMP-3, -10,
and IL-6 mRNA compared with no-salt Alport mice. MMP-
12 was elevated in both groups, but not significantly different
in salt versus no-salt groups. This is consistent with
biomechanical stretch experiments in cultured podocytes
(Figure 2). In wild-type mice, salt treatment did not result in
significant increases on any of the transcripts analyzed,
suggesting that the biomechanical influence of hypertension
is more pronounced in the Alport mice than in the wild-type
mice. We did not observe a statistical significance in lifespan
of salt-treated versus no-salt Alport mice, likely owing to the
accelerated pace of renal disease progression on the 129 Sv/J
background.
DISCUSSION
The glomerular podocyte foot processes form an adhesive
interface basally with the GBM through integrin/cell matrix
interactions and laterally with the complex of proteins
comprising the slit diaphragm. These adhesions are integrated
with the cytoskeleton, and signal through a variety of
mechanisms that likely participate in functional maintenance
of these cellular and extracellular structures. In diseases that
result in glomerular hypertension, the adhesive interface will be
under abnormal biomechanical strain, which could conceivably
alter the receptor/GBM interactions and signaling. Others have
shown that biomechanical strain of podocytes in culture results
in the activation of adaptive (protective) responses such as
changes in the actin cytoskeleton,24,25 as well as maladaptive
(destructive) responses such as the induction of SPARC10 or the
induction of osteopontin.11,26
A common cause of Glomerular hypertension is the loss of
nephron mass resulting from progressive glomerulosclero-
sis.27 Thus the problem of hypertensive influence on
glomerular homeostasis applies, in most instances, to later
phases of glomerular disease progression. Alport syndrome
presents a somewhat unique twist to this paradigm. As the
Alport GBM is thinner (owing to the absence of the type IV
collagen a3/a4/a5 network) and contains fewer interchain
disulfide crosslinks,3 it is likely to be more elastic than the
wild-type GBM. Under normotensive conditions, therefore,
the influences of biomechanical strain may be present before
nephron loss. These influences would be further exacerbated
by nephron loss and glomerular hypertension as a function of
progressive glomerulosclerosis. Thus, the influences of
biomechanical strain on Alport podocytes might be viewed
as a chronic insult that contributes to both the initiation and
progression of glomerular disease.
In an earlier work, we and others have shown that a
number of MMPs are induced in glomeruli from Alport
mice, and that the presence of elevated MMP activity is
linked to the deterioration of glomerular function in these
mice.4–6 In this paper, we show that many of the MMPs
(MMP-3, -9, -10, and -14) are induced in podocytes when
cells are exposed to biomechanical strain. However, the
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Figure 5 | Treatment of mice with salt elevates blood pressure
and increases proteinuria in C57Bl/6 X-linked Alport mice.
Mice were given either water or water containing N-nitro-L-
arginine methyl ester (L-NAME) salts at a dose of 50 mg/g body
weight based on known rate of water consumption. Blood
pressure measurements and urine collections were carried out
once per week from 6 to 9 weeks of age. (I) Salt-treated mice
showed consistently elevated blood pressure relative to non-salt-
treated mice (a). The urinary albumin bands were scanned and
values were normalized to urinary creatinine. There was a general
trend for increased blood pressure with age in both groups. With
a few exceptions, salt-treated animals showed higher levels of
proteinuria across all time points (b). An example of proteinuria
measurements is provided in (c), showing a Coomassie blue-
stained gel for weekly collections of salt and non-salt-treated
Alport mice, along with systolic blood pressure measurements.
(II) There is a direct correlation between systolic blood pressure
and proteinuria in C57 Bl/6 X-linked Alport mice. Blood pressure
values were plotted relative to the normalized albuminuria
measurements (arbitrary units) for eight Alport mice (five salt-
treated and three non-salt-treated). The data in (a) show that a
direct correlation exists between albuminuria and systolic blood
pressure for each time point. When all the data are combined in
panel (b), a highly significant correlation between blood pressure
and albuminuria is observed. Avg sys BP, average systolic blood
pressure.
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exceptions were MMP-2 and -12. Affymetrix data from 129
sv Alport mice at an early disease state (4 weeks of age)
compared with those from wild-type littermates showed that
IL-6 was significantly induced (unpublished observation).
Given that earlier studies in other systems showed IL-6
associated with stromelysin induction,28,29 and that IL-6 can
be induced by biomechanical strain,30,31 we surmised that
in vitro biomechanical strain studies might involve induction
of genes by both direct (adhesion dependent) and indirect
(autocrine activation by induced cytokine activity) mechan-
isms. This is indeed what we observed, as IL-6-neutralizing
antibodies partially ameliorate strain-mediated induction of
MMP-3 and -10 (Figure 3b), and as recombinant IL-6
induces MMP-3 and -10 in resting differentiated podocyte
cultures (Figure 3c).
In vivo correlates show a direct association of proteinuria
and systolic blood pressure, and exacerbated disease progres-
sion (based on matrix accumulation in the GBM and GBM
dysmorphology) in hypertensive Alport mice relative to non-
hypertensive Alport mice. IL-6, MMP-3, and MMP-10 were
markedly induced in the glomeruli from hypertensive Alport
mice relative to non-hypertensive Alport mice, whereas
MMP-12 was unaffected in the two groups. This is consistent
with the biomechanical strain studies using cultured
podocytes, suggesting that the biomechanical strain platform
may provide in vivo relevance in determining the specific
cellular mechanism underlying strain-mediated induction in
these cells.
The connection between biomechanical strain, adhesive
interactions, cell signaling, and MMP gene regulation has
been shown previously in both fibrochondrocytes and
vascular endothelial cells.32,33 This mechanism has not been
explored in glomerular podocytes and renal glomeruli, in
which the connection would be particularly relevant to
Alport glomerular pathology, given the established link
between MMP activity and glomerular disease progression.3–6
There are compelling clues in the literature. These include
conditional knockout mutations for integrin a3, integrin b1,
and the tetraspanin CD151 (known to bind to integrin a3
resulting in the high affinity ectodomain conformer of a3b1
Wild-type
LNα2
TEM
FN
Alport no salt Alport salt
Figure 6 |Hypertension induced by inclusion of N-nitro-L-arginine methyl ester (L-NAME) salt in the drinking water accelerates
glomerular disease progression in X-linked Alport mice. Mice were treated with salt from 6 to 10 weeks of age. Glomeruli were
immunostained for either fibronectin (FN) (a–c) or the a2 chain of laminin (LNa2) (d–f). Laminin a2 deposits in the glomerular basement
membrane (GBM) are denoted by arrowheads. Glomeruli from 10-week-old salt or non-salt-treated (6–10 weeks) animals were examined by
transmission electron microscopy (TEM) (g–i). Salt-treated animals with high systolic blood pressure consistently showed more extensive
GBM rarification and podocyte foot-process effacement than non-salt-treated animals with low systolic blood pressure. No differences were
observed in salt-treated wild-type mice compared with wild-type mice given normal drinking water (data not shown).
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integrin), which directly affect podocyte cell adhesion to
laminin 521 in the GBM,34–38 integrin-linked kinase, which
influences cytoskeletal organization and cell signaling
through the adhesive interactions of a3b1 integrin and its
GBM ligand,39,40 and a-actinin-4, which influences actin
cytoskeletal dynamics and integrin linked kinase (ILK)/
nephrin interactions as part of the adhesion interactome
complex.41 All of these mutations result in a common GBM
phenotype including multilaminated irregular thickening
associated with podocyte foot process effacement (the Alport
GBM phenotype). Collectively, these data support a model in
which disruption of the adhesive interactions between a3b1
integrin and laminin 521 disrupts the actin cytoskeleton and
activates adhesion-dependent signaling mechanisms (ILK
and/or focal adhesion kinase (FAK)), potentially resulting in
maladaptive responses.
These maladaptive responses may cause focal degradation
of the GBM, resulting in enhanced permeability (proteinuria)
and progression of glomerulosclerosis. Nephron loss further
exacerbates glomerular hypertension, resulting in progressive
acceleration to end-stage renal failure. This hypothesis is
supported by the observation that ramipril therapy, which
lowers blood pressure (and hence should decrease biome-
chanical strain), significantly slows the rate of glomerular
disease progression in Alport mice, and increases lifespan by
more than 100%.42 It will be of interest to determine whether
these components of the adhesive interface and signal
transduction machinery are mechanistically linked to
strain-mediated dysregulation of genes involved in the
pathobiology of Alport syndrome.
MATERIALS AND METHODS
Mice
Alport mice on the 129 Sv background were developed here1 and
bred in-house. Littermates were used as controls. C57 Bl/6 Alport
mice were described previously19 and were obtained from the
Jackson Laboratories (Bar Harbor, Maine). These animals were bred
as homozygotes, and age-matched C57 Bl/6 mice from the Jackson
Laboratories repository were used as controls. All experiments were
performed under an approved IACUC protocol and animals were
maintained in accordance to USDA standards. Every effort was
made to minimize stress and discomfort.
Derivation and maintenance of podocyte cell cultures
Wild-type podocyte cultures were established and cultured as
described previously.5 Differentiated podocytes were qualified
by immunofluorescence using primary antibodies against CD2AP
(H-290), WT-1 (C-19), VWF (H-300), and a-actinin-4 (N.17) all
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), synapto-
podin (SE-19, Sigma, St Louis, MO, USA), and Nephrin
(extracellular domain) a gift from R Kalluri. Podocyte cultures are
requalified frequently to assure consistency of the phenotype.43
Coating of Flexcell plate
Untreated six-well Bioflex plates (Flex International, Hillsborough,
NC, USA) were coated as follows: 3 mg/ml rat tail collagen type I
(BD Biosciences, Bedford, MA, USA) was diluted to 50 mg/ml in
filter-sterilized 0.02 N HOAc. In total, 1.25 ml of the collagen I
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Figure 7 | Treatment with N-nitro-L-arginine methyl ester
(L-NAME) salt increases proteinuria and expression of mRNAs
encoding matrix metalloproteinase (MMP)-3 and -10, and IL-6
in 129 Sv autosomal Alport mice. (I) Wild-type and Alport mice
were treated (or not) with L-NAME salt for 1 week between 4 and
5 weeks of age. Urine was collected, normalized to urinary
creatinine by dilution, fractionated on polyacrylamide gels, and
stained with Coomassie blue. Note that in some instances,
microalbuminuria is observed in salt-treated wild-type mice.
Alport mice showed an increase in proteinuria with salt treatment
(N¼ 3, a typical result is shown). Systolic blood pressure measures
are shown in parentheses. (II) Hypertension results in elevated
expression of IL-6, and MMP-3 and -10 mRNAs in glomeruli from
129 Sv Alport mice. Alport mice or wild-type littermates were
given either water or L-NAME salt in water from 4 to 5 weeks of
age (two animals per group). At 5 weeks of age, glomeruli were
isolated and RNA was analyzed in triplicate by real-time RT-PCR
for MMP-3, (c), -10 (b), and -12 and IL-6 (a) mRNA normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA,
which was run in multiplex. mRNAs for MMP-3 and -10, and IL-6
were significantly elevated in salt hypertensive Alport (denoted by
asterisks) mice relative to ‘normotensive’ Alport mice. MMP-12
was not significantly elevated in salt versus non-salt treated Alport
mice.
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solution was incubated on each well for 1 h at room temperature.
The wells were then aspirated, gently rinsed twice with Dulbecco’s
phosphate buffered saline (Caþ þ , Mgþ þ ), briefly air dried,
and either used or stored at 41C. A total of 100 mg of Laminin from
human placenta (Sigma) was diluted in 12 ml of Dulbecco’s
phosphate buffered saline (Caþ þ , Mgþ þ ) and 1 ml was
placed in each of the six collagen I-coated well at 371C for 2 h. The
wells were gently rinsed thrice with Dulbecco’s phosphate buffered
saline and used or stored at 41C.
Mechanical strain of cultured podocytes
Conditionally immortalized wild-type murine podocytes were
grown under non-permissive conditions (391C, no g-interferon)
for 10 days and plated onto Bioflex six-well plates coated with type I
collagen/placental laminin. Cells were plated in 5% fetal calf serum-
containing media at densities that result in 20–40% confluency.
0.5% fetal calf serum media were placed on the cells the next day.
After 48 h, the media were changed and the podocytes were exposed
to a regimen of 60 cycles of stretch and relaxation per minute
at a frequency of 0.5 Hz, with a maximum amplitude of 10%
radial surface elongation. The Flexercell Strain Unit FX4000
(Flexcell International, Hillsborough, NC, USA) was used to induce
stretch/relaxation for 15 h according to manufacturer’s directions.
Cells grown identically, but not exposed to stretch, were used
as controls.
Real-time PCR analysis
Sample preparation and real-time RT-PCR were performed on a
TaqMan ABI 7000 Sequence Detection System (Applied Biosystems,
Carlsbad, CA, USA). RT-PCR primers and conditions were as
previously described.5,6 TaqMan reagents for MMP-10
(Mm01168400_g1), IL-6 (Mm99999064_m1), and rodent GAPDH
containing both the primers and FAM-probes, and VIC-probe were
purchased from Applied Biosystems.
RT-PCR analysis
Semi-quantitative analysis of mRNA transcripts for MMP-2, -3, -9,
-10, -12, -14, and IL-6 was performed by RT-PCR as described
previously.44 Oligonucleotide primer pairs were as follows: for
GAPDH, 50-GGTGAAGGTCGGAGTCAACGGATTTGGTCG-30 and
50-GGATCTCGCTCCTGGAAGATGGTGATGGG-30 (236 bp target
size); for MMP-2, 50-CCTGATGTCCAGCAAGTAGATGC-30 and
50-TTAAGGTGGTGCAGGTATCTGG-30 (760 bp target size); for
MMP-3, 50-TGTACCCAGTCTACAAGTCCTCCA-30 and 50-CTGCG
AAGATCCACTGAAGAAGTAG-30 (685 bp target size); for MMP-9,
50-TTCTCTGGACGTCAAATGTGG-30 and 50-CAAAGAAGGAGC
CCTAGTTCAAGG-30 (414 bp target size); for MMP-10, 50-CTTCA
GACTTAGATGCTGCCTA-30 and 50-CAGGAGCAACTAATCATT
CTGAC-30 (533 bp target size); for MMP-12, 50-AAGCAACTGGG
CAACTGGACAACTC-30 and 50-GAGATACAAAGAAATGATGGA
TGC-30 (631 bp target size); and for MMP-14, 50-GTGATGGATG
GATACCCAATGC-30 and 50-GAACGCTGGCAGTAAAGCAGTC-30
and for IL-6, 50-CTTATCTGTTAGGAGAGCATTGG-30 and 50-GAG
ATACAAAGAAATGATGGATGC-30 (389 bp target size). All PCR
products were confirmed by DNA sequencing.
Measuring proteinuria
Urine samples were analyzed for albumin by polyacrylamide gel
electrophoresis gel analysis followed by staining with Coomassie blue
and scanning densitometry. Data were normalized to urinary creatinine,
which was measured using the QuantiChrom Creatinine assay kit
(DICT-500) according to the manufacturer’s instructions (BioAssay
Systems, Hayward, CA, USA). Samples from five mice per group (salt-
treated) and three mice per group (non-salt-treated) were run in
triplicate, and the mean values for each measurement were plotted.
Administration of L-NAME salts
We administered L-NAME at 50 mg/g body weight per day in the
drinking water. Blood pressure was monitored using the CODA-2
(Kent Scientific) non-invasive tail-cuff system. For C57 Bl/6 Alport
mice, five animals were given L-NAME salt, and three were given
normal water starting at 5 weeks of age. Urine samples were
collected at weekly intervals along with blood pressure measure-
ments and analyzed in triplicate for proteinuria. Animals were killed
at 10 weeks of age for analysis of glomerular pathology. For 129 Sv/J
mice, we treated three wild-type and three Alport mice with salt or
no salt from 4 to 5 weeks of age. Glomeruli were isolated using
magnetic beads as previously described.5
Immunofluorescence
Performed as described previously.5,6
Confocal analysis
Stretch and non-stretch wild-type podocytes were immunostained
for a-actinin-4 (N-17) and synaptopodin (SE-19) (Santa Cruz
Biotechnology), or FITC-phalloidin (Invitrogen, Carlsbad, CA,
USA) as described previously.5 Images were captured with a Zeiss
AxioPlan 2IF MOT microscope interfaced with a LSM510 META
confocal imaging system (Carl Zeiss, Munich, Germany).
Data presentation and statistical analysis
Data are expressed as mean±s.d. Differences between means were
tested for significance using Student’s t-test. Differences were
considered significant at the level of Po0.05.
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